Biohaven Pharmaceuticals, Inc:
Developing a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulation platforms. Internal development and research with intellectual property licensed from companies and institutions including BMS, AstraZeneca, Yale University, Catalent, ALS Biopharma and Massachusetts General Hospital.
Central Nervous System, Rare Disease
215 Church Street
New Haven, CT 06510
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by